This CME/CE activity is derived from content presented at the European Society of Cardiology Congress 2026 in Munich, Germany. The expert faculty, Prof. Tatjana Potpara, Prof. M. Cecilia Bahit and Dr. Christopher Granger, will first review the pharmacologic rationale for targeting factor XIa in SPAF and compare the mechanisms, efficacy benchmarks, and safety profiles of FXIa inhibitors versus DOACs, including their respective impacts on thrombotic protection and bleeding risk. Following, the faculty will examine clinical characteristics and risk profiles that may favor selecting an FXIa inhibitor over a DOAC for SPAF. Lastly, the faculty will discuss how to apply emerging FXIa inhibitor data to realistic SPAF patient scenarios to formulate individualized anticoagulation strategies, weighing ischemic stroke prevention against bleeding risk, and articulating how FXIa inhibition could shift current treatment paradigms for high-risk or undertreated patients.
Cardiologists including electrophysiologists and general cardiologists, other internists, PCPs/general practitioners, advanced practice providers, nurses, pharmacists, and other HCPs who contribute to the management of patients with atrial fibrillation and risk of stroke.
Describe the pharmacologic rationale for targeting factor XIa in SPAF and compare the mechanisms, efficacy benchmarks, and safety profiles of FXIa inhibitors versus DOACs, including their respective impacts on thrombotic protection and bleeding risk
Identify clinical characteristics and risk profiles (e.g., prior major bleeding, high HAS-BLED score, renal impairment, frailty, concomitant therapies) that may favor selection of an FXIa inhibitor over a DOAC for SPAF, should FXIa inhibitors become available
Apply emerging FXIa inhibitor data to realistic SPAF patient scenarios to formulate individualized anticoagulation strategies, weighing ischemic stroke prevention against bleeding risk, and articulating how FXIa inhibition could shift current treatment paradigms for high-risk or undertreated patients
Welcome and Introductions
FXI/XIa Hypothesis and Ongoing SPAF Trials
Practical Considerations
Case Resolution and Practical Guides
Faculty Panel Discussion and Audience Q&A
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Tatjana Potpara, MD, PhD, FESC
|
Honoraria: BSCI |
| Maria Cecilia Bahit, MD, FESC
|
Honoraria: Amgen Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Janssen; Novartis AG; Tenax Therapeutics |
| Christopher B. Granger, MD, FACC, FESC
|
Consultant/Advisor: Abiomed, Inc.; Amgen Inc.; Alnylam Pharmaceuticals, Inc.; Anthos Therapeutics; Boston Scientific Corporation; Bristol Myers Squibb; Cardionomic; CeleCor Therapeutics; F. Hoffmann-La Roche Ltd; Janssen; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Rhoshan Pharmaceuticals Inc.; Veralox Therapeutics
Grant/Research Support: Amgen Inc.; Alnylam Pharmaceuticals, Inc.; Bristol Myers Squibb; Duke Clinical Research Institute; F. Hoffmann-La Roche Ltd; Lilly USA, LLC; Novartis AG; Pfizer Inc.; Philips |
Timothy Hayes, MD, PhD; Kim Cheramie, PhD, MSN, RN, NPDA-BC; Joseph Feick, PharmD and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.75 hours of effective education time.
AcademicCME designates this enduring material for a maximum of 0.75 CNE Contact Hours (0.75 CNE Pharmacotherapeutic Contact Hours).
AcademicCME designates this continuing education activity for 0.75 CPE Contact Hours(0.075 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-26-023-H01-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from the Bristol Myers Squibb and Johnson & Johnson Alliance.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and the Bristol Myers Squibb and Johnson & Johnson Alliance do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
